2000 issue 4


Volume 16, issue 4


Farmakologiczne i kliniczne własności citalopramu

Jerzy Landowski1, Janusz Rybakowski2
1. I Klinika Chorób Psychicznych AM w Gdańsku
2. Klinika Psychiatrii Dorosłych AM w Poznaniu
Farmakoterapia w Psychiatrii i Neurologii, 2000, 4, 358-373


Citalopram belongs to the group of selective serotonin reuptake inhibitors (SSRI). Its antidepressive efficacy was proved in many double-blind studies using placebo. Controlled clinical studies showed it was comparable to others SSRI as well as tricyclic and tetracyclic antidepressants. Like others SSRI citalopram appeared to be effective in broad range of psychiatric disorders: panic disorder, obsessive-compulsive disorder, social phobia, eating disorders, premenstrual dysphoric disorder etc. Citalopram is well tolerated. It is a very weak inhibitor of CYP2D6, and the potential for pharmacokinetic interactions is low. There is a potential for developing the serotonin syndrome when combining citalopram with other drugs enhancing serotoninergic neurotransmission.